Ibogaine Safety Data

Evidence-based statistics from published clinical literature

QT Prolongation Risk

Significant

Mandatory EKG screening required before treatment

Reported Mortality (Unmonitored)

1 in 300-427

Alper et al. — includes polydrug use & pre-existing conditions

Clinical Setting Safety

Substantially Lower

With proper cardiac screening and continuous monitoring

Withdrawal Reduction

50-80%

Objective Signs of Opioid Withdrawal Scale (OOWS)

Noribogaine Half-Life

24-48 hours

Active metabolite extends therapeutic window

Required Pre-Screening

7 Tests

EKG, metabolic panel, CBC, thyroid, liver, kidney, medication review

Sources: Alper et al. (2012), Noller et al. (2018), Brown & Alper (2018), Mash et al. (2018). For complete citations and analysis, visit ibogainetreatmentguide.com/safety/cardiac-risks

Embed This Widget

Free to use on your website with attribution. Copy the code below:

<iframe src="https://ibogainetreatmentguide.com/embed/safety-stats/" width="100%" height="600" frameborder="0" title="Ibogaine Safety Statistics"></iframe>
<p style="font-size:12px;color:#666;margin-top:4px;">Data from <a href="https://ibogainetreatmentguide.com/safety/cardiac-risks/" target="_blank" rel="noopener">Ibogaine Treatment Guide</a></p>